Advertisement


Ronald J. Buckanovich, MD, PhD, on Ovarian Cancer: Expert Perspective on the SOLO2 Trial

2017 ASCO Annual Meeting

Advertisement

Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on health-related quality of life with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer. (Abstract 5507)



Related Videos

Breast Cancer

Gunter von Minckwitz, MD, on HER2+ Breast Cancer: Results From the APHINITY Trial

Gunter von Minckwitz, MD, of the German Breast Group, discusses study findings on a randomized comparison of chemotherapy, trastuzumab, and placebo vs chemotherapy, trastuzumab, and pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer. (Abstract LBA500)

Colorectal Cancer

Axel Grothey, MD, on Colon Cancer: Results of the IDEA Collaboration

Axel Grothey, MD, of the Mayo Clinic Rochester, discusses study findings on shortening the duration of adjuvant oxaliplatin-based therapy, linked to neurotoxicity, for patients with stage III colon cancer. (Abstract LBA1)

Hepatobiliary Cancer

John Marshall, MD, and John Neil Primrose, PhD, MBBS, on Biliary Tract Cancer: Results From the BILCAP Trial

John Marshall, MD, of Georgetown University, and John Neil Primrose, PhD, MBBS, of the University of Southampton, discuss the potentially practice-changing findings on adjuvant capecitabine for biliary tract cancer. (Abstract 4006)

Lung Cancer

Arnaud Scherpereel, MD, PhD, on Mesothelioma: Results From the IFCT-1501 MAPS2 Trial (French Language Version)

Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses in French phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesothelioma patients. (Abstract LBA8507)

Bruce E. Johnson, MD, and Julie Vose, MD, MBA: A Conversation With ASCO’s 2017–2018 President

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Bruce E. Johnson, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, discuss Dr. Johnson’s upcoming tenure as ASCO President and his goals for the year ahead.

Advertisement

Advertisement




Advertisement